IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0163567.html
   My bibliography  Save this article

Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data

Author

Listed:
  • Koen B Pouwels
  • Sefika E Bozdemir
  • Selen Yegenoglu
  • Solmaz Celebi
  • E David McIntosh
  • Serhat Unal
  • Maarten J Postma
  • Mustafa Hacimustafaoglu

Abstract

Background: Worldwide, respiratory syncytial virus (RSV) is considered to be the most important viral cause of respiratory morbidity and mortality among infants and young children. Although no active vaccine is available on the market yet, there are several active vaccine development programs in various stages. To assess whether one of these vaccines might be a future asset for national immunization programs, modeling the costs and benefits of various vaccination strategies is needed. Objectives: To evaluate the potential cost-effectiveness of RSV vaccination of infants and/or pregnant women in Turkey. Methods: A multi-cohort static Markov model with cycles of one month was used to compare the cost-effectiveness of vaccinated cohorts versus non-vaccinated cohorts. The 2014 Turkish birth cohort was divided by twelve to construct twelve monthly birth cohorts of equal size (111,459 new-borns). Model input was based on clinical data from a multicenter prospective study from Bursa, Turkey, combined with figures from the (inter)national literature and publicly available data from the Turkish Statistical Institute (TÜÏK). Incremental cost-effectiveness ratios (ICERs) were expressed in Turkish Lira (TL) per quality-adjusted life year (QALY) gained. Results: Vaccinating infants at 2 and 4 months of age would prevent 145,802 GP visits, 8,201 hospitalizations and 48 deaths during the first year of life, corresponding to a total gain of 1650 QALYs. The discounted ICER was estimated at 51,969 TL (26,220 US $ in 2013) per QALY gained. Vaccinating both pregnant women and infants would prevent more cases, but was less attractive from a pure economic point of view with a discounted ICER of 61,653 TL (31,106 US $ in 2013) per QALY. Vaccinating only during pregnancy would result in fewer cases prevented than infant vaccination and a less favorable ICER. Conclusion: RSV vaccination of infants and/or pregnant women has the potential to be cost-effective in Turkey. Although using relatively conservative assumptions, all evaluated strategies remained slightly below the threshold of 3 times the GDP per capita.

Suggested Citation

  • Koen B Pouwels & Sefika E Bozdemir & Selen Yegenoglu & Solmaz Celebi & E David McIntosh & Serhat Unal & Maarten J Postma & Mustafa Hacimustafaoglu, 2016. "Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data," PLOS ONE, Public Library of Science, vol. 11(9), pages 1-15, September.
    • Handle: RePEc:plo:pone00:0163567
    DOI: 10.1371/journal.pone.0163567
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0163567
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0163567&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0163567?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Mark Nuijten & Wolfgang Wittenberg & Maximilian Lebmeier, 2007. "Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children," PharmacoEconomics, Springer, vol. 25(1), pages 55-71, January.
    2. Anthony Bentley & Ivana Filipovic & Katherine Gooch & Katharina Büsch, 2013. "A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom," Health Economics Review, Springer, vol. 3(1), pages 1-12, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Marina Treskova & Francisco Pozo-Martin & Stefan Scholz & Viktoria Schönfeld & Ole Wichmann & Thomas Harder, 2021. "Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods," PharmacoEconomics, Springer, vol. 39(3), pages 287-315, March.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Gareth Thomas, 2018. "A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 177-187, March.
    2. Mark Nuijten & Wolfgang Wittenberg, 2010. "Cost effectiveness of palivizumab in Spain: an analysis using observational data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(1), pages 105-115, February.
    3. Ralph Schmidt & Istvan Majer & Natalia García Román & Alejandra Rivas Basterra & ElizaBeth Grubb & Constancio Medrano López, 2017. "Palivizumab in the prevention of severe respiratory syncytial virus infection in children with congenital heart disease; a novel cost-utility modeling study reflecting evidence-based clinical pathways," Health Economics Review, Springer, vol. 7(1), pages 1-14, December.
    4. Colette Mankowski & Sachin Patel & David Trueman & Anthony Bentley & Chris Poole, 2016. "Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland," PLOS ONE, Public Library of Science, vol. 11(3), pages 1-16, March.
    5. Anthony Bentley & Ivana Filipovic & Katherine Gooch & Katharina Büsch, 2013. "A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom," Health Economics Review, Springer, vol. 3(1), pages 1-12, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0163567. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.